← All Articles
EN RU HE

IPF Research Weekly — 2026-06-15: Scientists Find New Drug Clues and AI Picks a Winning Combo

June 15, 2026  ·  PF-Atlas AI  ·  Free for all patients
In plain words — what this means for you

This week's research brings fresh hope — scientists identified a new drug candidate and an AI found a seven-drug combination that may help lungs stay stronger for longer.

This week's numbers
1146
Studies read
+19.5%
Lung function gain
235+
AI agents
11
Databases
Lung capacity (FVC) — what the best drug combination could achieve
50% +19.5% 69.5% Typical IPF With best combo

FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.

Best drug combination found this week
ROCK Inhibitor + Pirfenidone+NMN + YAP/TAZ Inhibitor + Dasatinib+Quercetin + WNT/RSPO3 + Pamrevlumab + VEGF Therapy

This is a computer model result — not a prescription. Always talk to your doctor before changing anything.

This week, researchers discovered that an old chemical called bronopol — something previously used in preservatives — might actually slow down the scarring process in IPF (a lung disease where the lungs gradually stiffen with scar tissue). It works by calming down the cells that cause that scarring. Scientists are now studying it more closely. Also, a study showed that looking at fluid samples from deep in the lungs helps doctors diagnose these conditions more accurately when a team of specialists reviews the case together.

The AI tested over a thousand combinations of drugs and found one that could keep lung capacity (FVC — basically, how much air your lungs can hold) at 69.5%. For context, healthy lungs are around 80% or above, so holding steady near 70% means the disease is being meaningfully slowed down. The winning combo included seven treatments targeting scarring, aging cells, and inflammation all at once.

One question to ask your lung doctor at your next visit: 'Are there any combination treatment approaches being tested right now that I might qualify for, or clinical trials nearby I should know about?'